Fulcrum ends sickle cell ambitions following regulatory feedback, will seek exit

June 2, 2026 07:21 AM EDT StartupsR&D Ful­crum ends sick­le cell am­bi­tions fol­low­ing reg­u­la­to­ry feed­back, will seek ex­it Kyle LaHucik Biotech Correspondent Ful­crum Ther­a­peu­tics is scrap­ping its sole clin­i­cal-stage med­i­cine af­ter feed­back from the FDA that ref­er­enced a re­cent­ly pulled can­cer drug from Ipsen. Ful­crum had Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER